You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
永泰生物-B(06978.HK)中期研發開支同比增加約13.0%至1.07億元
格隆匯 08-24 09:29

格隆匯8月24日丨永泰生物-B(06978.HK)8月23日晚間公吿,集團的研發開支由截至2020年6月30日止6個月約人民幣9500萬元增加約13.0%至截至2021年6月30日止6個月約人民幣1.07億元,主要是由於報吿期間的研發員工人數上升及產品研發管線增加。

公司是中國一家領先的細胞免疫治療生物醫藥公司,接近15年來專注於T細胞免疫治療的研發和商業化。EAL®-公司的核心在研產品-屬多靶點細胞免疫治療產品,在臨牀應用方面積累了超過十年的往績,並對多種癌症顯示出治療效果。公司於2006年起開展有關EAL®的研究,對細胞培養體系和方法進行了改進,並開發出具有獨立知識產權、用於生產EAL®細胞的專有技術平台。

公司選擇了預防肝癌術後復發作為EAL®臨牀試驗的臨牀適應症。公司計劃待臨牀試驗的結果達到統計學意義後,提交申請將EAL在中國市場商業化。

公司的產品管線覆蓋非基因改造及基因改造產品,以及多靶點及單靶點產品等主要類別的細胞免疫治療產品。除EAL®外,公司的主要在研產品包括6B11、CAR-T細胞系列及TCR-T細胞系列。

公司的技術核心團隊由資深癌症免疫學家組成,具有行業前瞻性和敏感性。公司建立了從早期研發、臨牀前研究、臨牀研究直至商業化生產和管理的研發組織結構,使得產品研發能夠快速推進。

公司亦已建立細胞免疫治療產品研發所需的技術平台,並設立一個用於臨牀試驗的組織及管理平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account